Zobrazeno 1 - 10
of 35
pro vyhledávání: '"S. V Voloshin"'
Autor:
E. A. Dmitrieva, S. V. Voloshin, K. D. Kaplanov, V. Touliet, V. V. Zasypkina, O. V. Magdych, E. F. Klinushkina
Publikováno v:
Онкогематология, Vol 19, Iss 3, Pp 79-91 (2024)
Background. Chronic lymphocytic leukemia (CLL) is a slowly progressive malignant disease that results in uncontrolled proliferation and accumulation of B-lymphocytes in the blood and bone marrow, and is the most common form of leukemia in Western cou
Externí odkaz:
https://doaj.org/article/f479661df1be4948a604e805204e6a72
Autor:
E. O. Kunevich, I. S. Martynkevich, M. A. Mikhaleva, А. N. Bogdanov, E. V. Motyko, A. Yu. Kuvshinov, S. V. Sidorkevich, S. V. Voloshin
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 181-195 (2023)
Aim. To study the prognostic significance of gene mutations and intracellular signaling pathways involved in lymphomagenesis in patients with follicular lymphoma using next generation sequencing (NGS).Materials and methods. The prospective study incl
Externí odkaz:
https://doaj.org/article/9be315686e504add8729ebae288c913c
Publikováno v:
Медицинская иммунология, Vol 25, Iss 5, Pp 1253-1258 (2023)
Bruton's tyrosine kinase (BTK) inhibitors represent a class of drugs that have demonstrated their efficacy and safety in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphomas who were considered refractory to any previously used type
Externí odkaz:
https://doaj.org/article/ee66538cb9314d519d421931cb9b9cf1
Autor:
D. F. Mylostуva, S. J. Farafonov, O. М. Puzniak, V. І. Stakhiv, V. V. Borshchenko, S. V. Tsisinska, S. V. Voloshin
Publikováno v:
Regulatory Mechanisms in Biosystems, Vol 14, Iss 1, Pp 106-111 (2023)
Active forms of oxygen are formed in the course of the organism's vital activity in biochemical reactions. These forms, when the pro/antioxidant balance is disturbed, trigger a cascade of lipid peroxidation, which can be the cause of the development
Externí odkaz:
https://doaj.org/article/e0a1e5043af84b5d9f028b392f904a7f
Autor:
S. V. Voloshin, A. D. Garifullin, A. A. Kuzyaeva, N. N. Sinitsina, N. N. Alekseeva, A. V. Schmidt, S. Y. Linnikov, V. A. Shuvaev, A. Y. Kuvshinov, N. A. Potikhonova, A. V. Seltser, V. A. Balashova, Z. V. Chubukina, A. N. Bogdanov, S. V. Sidorkevich
Publikováno v:
Онкогематология, Vol 17, Iss 2, Pp 82-94 (2022)
Background. An autologous stem cell transplant (ASCT) is the standard of treatment young and fit patients with multiple myeloma (MM). The using this method of treatment is limited due to the high consumption of economic and intellectual resources, th
Externí odkaz:
https://doaj.org/article/ba5035f4e8584c528007a5cbbdb9e285
Autor:
S. V. Voloshin, S. Yu. Linnikov, A. D. Garifullin, A. A. Kuzyaeva, A. V. Shmidt, A. Yu. Kuvshinov, A. N. Bogdanov, M. A. Mikhileva, I. S. Martynkevich, M. N. Zenina, S. V. Sidorkevich
Publikováno v:
Онкогематология, Vol 17, Iss 1, Pp 26-36 (2022)
Background. Over the past 15 years, the therapeutic breakthrough in the treatment of multiple myeloma observed primarily due to the emergence of new drugs. Since the characteristic of the disease is a chronic course with consecutive periods of remiss
Externí odkaz:
https://doaj.org/article/950e83cca2944d5084a1c58c5bd58213
Autor:
N. A. Romanenko, A. E. Alborov, S. S. Bessmeltsev, E. R. Shilova, S. V. Voloshin, A. V. Chechetkin
Publikováno v:
Онкогематология, Vol 15, Iss 3, Pp 95-106 (2020)
Anemia in patients with malignant neoplasms affects the quality of life of the patient and sometimes limits the timely implementation of antitumor treatment. In the pathogenesis of anemia of the malignant neoplasms the largest role play infiltration
Externí odkaz:
https://doaj.org/article/50882136b57b4b10bfe3d3cdd93e5d8e
Autor:
A. A. Zhernyakova, I. S. Martynkevich, V. A. Shuvaev, L. B. Polushkina, M. S. Fominykh, V. Yu. Udal’eva, I. I. Zotova, D. I. Shiсhbabaeva, S. V. Voloshin, S. S. Бессмельцев, A. V. Chechetkin, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 12, Iss 2, Pp 30-38 (2017)
Background. Thrombosis and hemorrhage are the main category of complications, that affects the overall survival (OS), quality of life and therapy option choice in essential thrombocythemia (ET). Molecular marker presence (JAK2V617F (JAK2+), MPL (MPL+
Externí odkaz:
https://doaj.org/article/ff4d08c63d6c4263aec7f738cf2269b0
Autor:
S. V. Voloshin, S. S. Bessmeltsev, T. P. Zagoskina, N. V. Medvedeva, K. D. Kaplanov, E. V. Karyagina, A. D. Garifullin, A. Yu. Kuvshinov, L. V. Stelmashenko, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 10, Iss 3, Pp 10-17 (2015)
Relapsed and refractory (R/R) multiple myeloma (MM) constitutes a specific and unmet medical need. Median survival ranges from as little as 6 to 9 months, and responses to treatment are characteristically short. In patients with R/R MM after therapy
Externí odkaz:
https://doaj.org/article/3a9bc84bcc124ee88a5b7e2d94b39c1b
Autor:
S. V. Voloshin, Yu. A. Krivolapov, A. V. Shmidt, V. A. Shuvaev, M. S. Fominykh, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 8, Iss 2, Pp 8-21 (2014)
In this article we present the most up-to-date information about etiology, pathogenesis, diagnostic and treatment principles of primary central nervous system diffuse large B-cell lymphoma. We propose algorithm of diagnosis and treatment based on lit
Externí odkaz:
https://doaj.org/article/da6112ef097c4217bf14ef33dfc36ea5